[Antagonism of LY333531 on high glucose induced permeability upregulation of cardiac microvascular endothelial cells].
OBJECTIVE
To investigate the antagonism of LY333531 on the increased permeability of cardiac microvascular endothelial cells (CMECs) induced by high glucose.


METHODS
The cultured CMECs from rats were randomly divided into four groups: normal group, high glucose group (25 mmol/L), high glucose+LY333531 (10 micromol/L) group and high glucose+saline group. The permeability of cell monolayer was detected using in vitro vascular permeability assay kit. Cell apoptosis was determined by TUNEL and the expression of PKCbeta II was analyzed by immunofluorescence and Western blot in each group.


RESULTS
Compared with normal group, the permeability (400.0+/-20.00 vs 223.3+/-25.17; P<0.01) of cell monolayer cultured in high glucose medium was increased at a higher apoptosis rate (55.00%+/-5.000% vs 2.333%+/-1.155%; P<0.01) and PKCbeta II expression (0.4767+/-0.0751 vs 0.1733+/-0.0208; P<0.01). However, the high glucose+LY333531 group showed noticeable attenuation on both permeability (360+/-17.32 vs 400.0+/-20.00; P<0.05) and apoptosis (25.00%+/-5.000% vs 55.00%+/-5.000%; P<0.01) with reduced PKCbeta II expression (0.2800+/-0.0700 vs 0.4767+/-0.0751; P<0.01). No significant effects of saline on the cell permeability, apoptosis and PKCbeta II expression were observed.


CONCLUSIONS
The antagonism of LY333531 has shown obvious effects on the impairment of high glucose to the permeability of CMECs.
Yin
Zhi-yong
ZY
Cardiovascular Department, Xijing Hospital, the Fourth Military Medical University, Xi'an 710032, China. wanghc@fmmu.edu.cn
Wei
Li-ping
LP
Hao
Yuan-yuan
YY
Zhang
Rong-qing
RQ
Li
Cong-ye
CY
Wang
Hai-chang
HC
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D002199:Capillary Permeability / Q000187:drug effects*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005455:Fluorescent Antibody Technique; D005947:Glucose / Q000494:pharmacology*; D020287:In Situ Nick-End Labeling; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D008301:Maleimides / Q000494:pharmacology*; D009206:Myocardium / Q000166:cytology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D064546:Protein Kinase C beta; D051381:Rats; D017207:Rats, Sprague-Dawley; D015854:Up-Regulation / Q000187:drug effects
D004791:Enzyme Inhibitors; D007211:Indoles; D008301:Maleimides; C099154:ruboxistaurin; D011493:Protein Kinase C; D064546:Protein Kinase C beta; D005947:Glucose